Human Biomonitoring for Exposure to Bisphenol A (BPA) and Potential Replacement Products

<p>
<ol>
<li>Provide human biomonitoring data for BPA and its structural analogs that are potential replacement products in adults exposed occupationally to thermal-paper cash register receipts. The routes of administration (dermal/oral) are likely key determinants of internal exposure to the active unconjugated form of BPA and/or possible replacements. These data will be used for physiologically based pharmacokinetic (PBPK) modeling along with existing pharmacokinetic data from experimental animals and humans.</li>
<li>Provide estimates of concentrations of active BPA aglycone in potential target tissues of developing fetuses and children for BPA and/or structural analogs from all possible exposures, particularly from food and medical devices, so FDA can make science-based decisions on risks from BPA and possible replacement products.</li></ol></p>